Key players in Insulin Biosimilars
In the order our report profiles them, not ranked by sales. Each name opens the company's page with its public records.
| # | Company | Website | Our reports |
|---|---|---|---|
| 1 | Biocon | — | 132 reports |
| 2 |  Viatris |
viatris.com (opens in a new tab) | 264 reports |
| 3 |  Sanofi |
sanofi.com (opens in a new tab) | 1,386 reports |
| 4 |  Eli Lilly and Company |
lilly.com (opens in a new tab) | 1,056 reports |
| 5 | Gan & Lee Pharmaceuticals | — | 33 reports |
| 6 |  Wockhardt Ltd. |
wockhardt.com (opens in a new tab) | 66 reports |
Also active in Insulin Biosimilars
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
| Company | Where public records show them |
|---|---|
 Novo Nordisk A/S |
|
Source: WHO Prequalification, Vaccines, tests and medicines on the WHO prequalified lists that match this market. Retrieved 13 Nov 2026.
Insulin Biosimilars reports by place
Australia
Brazil
Canada
China
Ecuador
Egypt
France
Germany
Hong Kong
India
Italy
Japan
Kenya
Malaysia
Mexico
New Zealand
PhilippinesGet the full Insulin Biosimilars report
Company profiles, market shares and strategies come with the full report, with researched size, forecast, growth and segments.
Key players are our report's research. Other companies and trial counts come from free public records, each with its source. Acuitas market figures are not published on this page.